J Neurocytol. 2003 Mar;32(3):265-76
Rosenbluth J, Schiff R, Liang WL, Dou W.
Department of Physiology and Neuroscience and Rusk Institute, New York University School of Medicine, 400 East 34 Street, New York, NY 10016, USA.
We showed previously that spinal cord implants of hybridoma cells (O1) that secrete an IgM antigalactocerebroside cause focal multiple-sclerosis-like plaques of demyelination followed by remyelination to form "shadow plaques" (Rosenbluth et al., 1999).
The antibody in that case was directed against a glycolipid present in mature oligodendrocytes and myelin but not in precursor cells.
We now report the effects of implanting a different hybridoma (O4) that secretes IgM antibodies directed against sulfatide, a constituent not only of mature myelin and oligodendrocytes but also of late precursor cells, in order to determine whether this hybridoma too would generate focal demyelination and would, in addition, block remyelination.
Our results show that focal plaques of demyelination indeed appear after O4 implantation, and that remyelination does occur, but only in cases where the hybridoma cells have degenerated, probably through host rejection.
The occurrence of remyelination suggests that oligodendrocyte precursor cells are capable of migrating in rapidly from adjacent areas or that early precursors, not yet expressing sulfatide, remain undamaged within the lesions.
In cases where intact hybridoma cells persist at lesion sites, remyelination does not occur.
Failure of remyelination in this model thus appears to result from the continuing presence of antimyelin antibodies rather than from depletion of oligodendrocyte precursors.